XBIO - Xenetic Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Xenetic Biosciences, Inc.

40 Speen Street
Suite 102
Framingham, MA 01701
United States
781-778-7720
http://www.xeneticbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey F. EisenbergCEO & Director318.33kN/A1966
Mr. James F. ParslowCFO, COO & Corp. Sec.287.6kN/A1965
Dr. Curtis A. LockshinChief Scientific Officer259.58kN/A1960
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progestin resistant endometrial cancer. It is also developing ErepoXen, a drug using PolyXen platform technology for the treatment of anemia in chronic kidney disease patients. The company has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Corporate Governance

Xenetic Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.